The 1989 patterns of care study for prostate cancer: five-year outcomes

Chuba, Paul J.; Moughan, Jennifer; Forman, Jeffrey D.; Owen, Jean B.; Hanks, Gerald E.

doi:10.1016/s0360-3016(01)01478-x

Cited by 32 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical TNM stage, histopathological Gleason score (GS) and prostate-specific antigen (PSA) are established prognostic factors for groups of patients with PC, 1 but are insufficient in predicting the individual course of the disease. Curative treatment strategies in patients with localized or locally advanced PC attempt to eradicate the tumor either by radical prostatectomy or radiotherapy (RT).…”

mentioning

confidence: 99%

Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy

Berg

Berner

Lilleby

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

The purpose of this study was to explore whether detection of disseminated tumor cells (DTCs) in bone marrow (BM) of nonmetastatic prostate cancer (PC) was associated with other clinical or histopathological factors at diagnoses or clinical outcome subsequent to definitive radiotherapy (RT). We evaluated BM aspirates from 272 cT 1-4 pN 0 M 0 PC patients by immunocytochemistry employing anticytokeratin antibodies (AE1/AE3). BM-status was compared with clinical and histopathological parameters. Longterm clinical outcome was assessed in 131 of the patients who all had completed definitive RT with or without androgen deprivation (AD), initiating treatment >5 years before cut-off date June 1, 2005. They had at least 1 unfavorable prognostic feature defined as cT [3][4] or Gleason score (GS) ≥7B or PSA ≥10 lg/l. Overall death, cause-specific death, distant metastases (DM) as first clinical relapse, local failure as first clinical relapse and biochemical failure were defined as end-points. DTCs were detected in 18% of the patients and were associated with increasing GS (p 5 0.04) and percentage of Gleason pattern 4/5 (p 5 0.04). The 7-year cumulative risk of DM was 21% for BM-positive patients vs. 6% for BM-negative patients (p 5 0.07). In patients receiving RT without AD (n 5 75), the 7-year cumulative risk of DM for BM-positive patients was 28% vs. 9% for BM-negative patients (p 5 0.03). BM-status did not have impact on other end-points. In conclusion our study shows that presence of DTCs in BM at diagnosis was associated with the histological differentiation of the primary tumor and an increased risk of developing distant metastases after RT. ' 2007 Wiley-Liss, Inc.

show abstract

mentioning

confidence: 99%

Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy

Berg

Berner

Lilleby

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…radiotherapy alone experience clinical progression, and 26-43% die within 5 years of initiating treatment (Roach et al 2000;Chuba et al 2001;Vicini et al 2002). The high-precision technique, conformal radiotherapy, has improved local control through dose escalation without increasing morbidity (Hanks et al 1999).…”

mentioning

confidence: 99%

The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer

See

Tyrrell

2006

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

In patients with locally advanced disease, bicalutamide 150 mg adjuvant to radiotherapy demonstrates significant clinical benefits in terms of overall survival, PFS and PSA-PFS compared with radiotherapy alone. The overall survival benefit in these patients is consistent with prior studies evaluating castration-based therapies adjuvant to radiotherapy (Bolla et al. in Lancet 360:103-108, 2002; Pilepich et al. in Int J Radiat Oncol Biol Phys 61:1285-1290, 2005). In addition, the clinical benefit of bicalutamide 150 mg in locally advanced patients, but not in those with localized disease, is consistent with the overall results from the EPC program (McLeod et al. BJU Int 97:247-254, 2006). Given the quality-of-life advantages of bicalutamide relative to castration, bicalutamide 150 mg adjuvant to radiotherapy is an attractive alternative for men with locally advanced prostate cancer.

show abstract

“…So betragen die Raten für das 3-Jahres-bNED 43-77% [6,9,10] und für das 5-JahresbNED 14-79% [8,14,19,22,24,26,28,30,35,42]. Eine Übersicht über die biochemischen Kontrollraten nach definitiver Strahlentherapie des Prostatakarzinoms findet sich in Tabelle 4.…”

Section: Diskussionunclassified

“…Die Heterogenität der Ergebnisse spiegelt unter anderem die unterschiedliche Zusammensetzung der Kollektive hinsichtlich der prognostischen Faktoren wider. Als prognostische Faktoren für das Auftreten eines biochemischen Rezidivs gelten der initiale, prätherapeutische PSAWert, das T-Stadium, der Differenzierungsgrad des Tumors und therapieassoziierte Faktoren, wobei vor allem das prätherapeutische PSA eine herausragende Rolle spielt [6,8,9,14,19,26,28,30,34,35,42,43]. Auch in unserem Kollektiv war das initiale PSA der wichtigste, vor Therapie bestimmbare Prognosefaktor in Bezug auf das biochemisch rezidiv-freie Überleben.…”

Section: Diskussionunclassified

See 1 more Smart Citation

Biochemische Kontrolle nach konformaler, dreidimensionaler Strahlentherapie des Prostatakarzinoms

Geinitz

Zimmermann

Wedel

et al. 2002

Strahlentherapie und Onkologie

View full text Add to dashboard Cite

Despite of having higher initial PSA-values patients treated with conformal radiotherapy and short-term neoadjuvant hormonal therapy had the same bNED survival as patients treated with conformal radiotherapy alone. Patients with initial PSA values above 20 ng/ml, with T3 or T4 disease or with poorly differentiated tumors had a low biochemical control. For this group of patients intensified therapy should be considered.

show abstract

The 1989 patterns of care study for prostate cancer: five-year outcomes

Cited by 32 publications

References 36 publications

Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy

Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy

The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer

Biochemische Kontrolle nach konformaler, dreidimensionaler Strahlentherapie des Prostatakarzinoms

Contact Info

Product

Resources

About